drugset / Trial / NCT06873659
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2025-02-26
- Primary completion
- 2027-04
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SON-DP | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | SON-DP | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | SON-DP | Protein / enzyme biologic | 4.5 mg/kg | Intravenous |
| Subject | SON-DP | Protein / enzyme biologic | 6 mg/kg | Intravenous |